Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Employee Stories
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
Month
1
2
3
4
5
6
7
8
9
10
11
12
27
2021-09
Boan Biotech's Dulaglutide Injection (BA5101) Approved for Clinical Trials in China
26
2021-09
Boan Biotech to Present the Pre-clinical Data of Its Proprietary CD3+ T-cell Engager Platform and CEA/CD3 Bispecific Antibody at World Bispecific Summit
20
2021-08
Boan Biotech’s Neutralizing Antibody against SARS-CoV-2 Shows Efficacy against Lambda and Other Variants
28
2021-07
New Indication for Boan Biotech’s Boyounuo (Bevacizumab Injection) Approved in China
24
2021-06
Boan Biotech Publishes Research Results for CEA/CD3 Bispecific Antibody in Antibody Therapeutics
05
2021-06
Boan Biotech’s 博优诺® (Bevacizumab Injection) Launched along with Patient Assistance Program
26
2021-05
Boan Biotech Grants AstraZeneca Exclusive Rights to Promote 博优诺® (Bevacizumab Injection) in Specific County Markets of China
07
2021-05
Boan Biotech's 博优诺® Obtains Marketing Authorization in China
06
2021-05
Boan Biotech Obtains Approval for Initiating Clinical Trial for Nivolumab Injection (LY01015) in China
06
2021-05
Boan Biotech’s Neutralizing Antibody against SARS-CoV-2 Completes Phase I Clinical Trial in China, With Good Results in Safety and Tolerance
4
5
6
7
8
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
